卡泊芬净与伏立康唑在中性粒细胞缺乏伴发热患者中初始经验性抗真菌治疗的经济学评价

发布时间：2018-06-21 03:18

本文选题：卡泊芬净 + 伏立康唑　；参考：《中国药房》2017年14期

【摘要】：目的:对卡泊芬净与伏立康唑在中性粒细胞缺乏伴发热(以下简称"粒缺发热")患者中初始经验性抗真菌治疗的方案进行经济学评价。方法:基于两项关于卡泊芬净与伏立康唑初始经验性抗真菌治疗粒缺发热的国际多中心临床试验,结合国内临床专家对疾病治疗过程中药物选择方面的意见,构建决策树模型,运用Tree Age Pro 2011软件分析卡泊芬净与伏立康唑作为初始经验性抗真菌药物分别治疗10 d的成本效果。结果:卡泊芬净组患者的直接医疗费用低于伏立康唑组(52 826.71元vs.58 246.70元),治疗成功率和患者生存率均高于伏立康唑组(分别为33.95%vs.25.63%、92.36%vs.91.87%)。无论是以治疗成功率还是以患者生存率为效果指标,卡泊芬净组的成本-效果比均小于伏立康唑组,且增量成本-效果比和敏感度分析结果均证实了此结果。结论:对粒缺发热患者进行初始经验性抗真菌治疗,卡泊芬净比伏立康唑更具有成本效果优势。
[Abstract]:Objective: to evaluate the initial empirical antifungal therapy regimen of carpofen and voriconazole in patients with neutrophil deficiency and fever (hereinafter referred to as "fever of granulocytosis"). Methods: a decision tree model was established based on two international multi-center clinical trials on the initial empirical antifungal therapy of carpofentine and fulconazole in the treatment of hypogranulocytic fever, combined with the opinions of domestic clinical experts on drug selection in the course of disease treatment. Tree Age Pro 2011 software was used to analyze the cost-effectiveness of captophannet and volconazole as initial empirical antifungal drugs for 10 days. Results: the direct medical cost of carpofen group was lower than that of Veconazole group (52 826.71 yuan vs.58 246.70 yuan), the success rate of treatment and the survival rate of patients were both higher than those of fulconazole group (33.95% vs 25.63 92.36vs.91.87). Both the success rate of treatment and the survival rate of patients were taken as effective indexes, and the cost-effectiveness ratio of carpofentine group was lower than that of fulconazole group, and the results of incremental cost-effect ratio and sensitivity analysis confirmed the results. Conclusion: Carpofen is more cost effective than Vriconazole in the initial experience of antifungal therapy in patients with fever with hypogranulocytosis.
【作者单位】：复旦大学公共卫生学院/卫生部卫生技术评估重点实验室;
【分类号】：R519

【相似文献】